26 December 2020 in Open Access Macedonian Journal of Medical Sciences
GNGiovanni Francesco Nicoletti
Giovanni Francesco Nicoletti
+1
BACKGROUND: Hyaluronic acid fillers are the most used worldwide, thanks to the high biocompatibility and safety profile of HA and it is also the only substance that can be “dissolved” due to the hyaluronidase effect. AIM: A retrospective clinical evaluation of the outcomes following PEG cross-linked HA-based filler injection was performed. METHODS: Data were collected from December 2017 to June 2020. A total of 65 patients (12 M, 53 F), age ranging 28–62 year’s old (mean age 42.3), were treated. Exclusion criteria were applied and in accord to treatment plan, were used specific site injections and fillers. Follow-up was evaluated between 6 months and 2 years. RESULTS: A total of 61 treatments using 124 vials of HA filler crosslinked with PEG were performed. CONCLUSION: In conclusion, from 2014, HA fillers having PEG as cross-linker agent have been introduced in the european market. Several papers have been published in order to evaluate the features of these fillers, although, to the best of our knowledge, this is the first clinical paper regarding their use.
1 May 2026 in Clinical, Cosmetic and Investigational Dermatology
Introduction and Purpose: Anatomic factors and age‑related changes in the midface, along with sun exposure, prolonged television viewing, anemia, and hormonal derangements, contribute to the development of periorbital hyperpigmentation, also known as dark circles. Intradermally injected PN HPT (Polynucleotides High Purification Technology) from trout gonads has an immediate volume-enhancing effect and a longer-term indirect restructuring action on dermal and subdermal tissues. Methods: Open-label multinational observational cohort of 61 real-life multinational subjects of both genders and unskewed age distribution (mean 41.5 ± 10.5 years, range 20 to 67), with subjectively disturbing dark circles across all Huang subtypes. PN HPT hydrogel (7.5 mg/mL) in phosphate buffer was administered with needle or cannula at baseline (T0), after two to three weeks (second injection, T1), and two to three weeks after T1 (third injection, T2); usually 1 mL on the right periorbicular area and 1 mL on the left (lower doses allowed at the specialist’s discretion). Post-treatment follow-up visits: Snapshot photographs were taken at 1 month (T3) and three months after the final T2 injection (T4) and digitally analyzed for color, pigmentation, and outcomes compared with T0 (primary endpoint). Every participating specialist and every treated subject also assessed hyperpigmentation and skin quality categories with GAIS-like scoring scales. Results: Regarding the primary endpoint, the overall picture showed a generalized, highly significant shift toward less severe periorbital hyperpigmentation (p < 0.001), especially among needle-treated subjects with the structural subtype. The progressive improvements at T3 and T4 in the evaluated perceptual skin quality categories were also remarkable for both participating specialists and treated subjects. Conclusion: The double-edged rationale of low-concentration PN HPT — immediate correction of hollows and tissue loss, and longer-term restructuring of periorbital connective tissues — may be a sound option for improving the appearance of dark circles and the lives of subjects with this aesthetic nuisance.